Autoimmune hemolytic anemia, abbreviated as AIHA, is a somewhat uncommon type of anemia, during which a person’s body develops and produces antibodies that are targeted against its own red blood cells. This causes a unfortunate phenomenon where the premature and permanent destruction of these cells is accomplished over time. Liposomal clodronate is a substance that has recently caught the eye of many medical and health scientists, and it is currently being studied and tested as a potential treatment for AIHA.
In a vast number of cases, surgery must be performed to treat the aforementioned disorder. As most people are aware of, surgery of any type can result in complications. This is particularly true if the patient is of an advanced age or has additional health issues or underlying diseases.
Individuals who have poor immune systems are usually not appropriate candidates for surgical procedures. In addition, people who take specific drugs may have an increased risk for complications following surgery. This is why most of the clinical studies involving AIHA concentrate on finding new drugs with which to treat the disorder, instead of additional surgical options.
Fortunately, today’s modern technology has allowed scientists to isolate the type of agent that is needed to correct the red blood cell destruction that is caused by AIHA: antimacrophage agents are essential in order to stop the destructive activity occurring within the bloodstreams of individuals suffering from AIHA.
According to recent research, liposomally encapsulated clodronate can successfully combat the abnormal production of the antibodies that attack one’s red blood cells. Additional trials were conducted to find out if these discoveries were truly as positive as the initial studies indicated.
A two-year study was conducted on mice to test the effectiveness of the drug mentioned above. Two highly different red blood cell antibodies were administered to 2 groups of laboratory mice. The speed at which the destruction of the red blood cells took place dropped significantly when liposomal clodronate was given to both groups of mice.
Health researchers and experts are optimistic concerning this drug and its potential benefits for AIHA patients. Many scientists are of the opinion that the use of this drug may offer the same health benefits as a medical procedure referred to as a medicinal splenectomy. Of course, the use of liposomally encapsulated clodronate would certainly be much less complicated than virtually any surgery. The substance may also be helpful in cases where a quick response to treatment is imperative.
In addition, positive results were observed when liposomal clodronate was used to suppress macrophage activity in various situations. These included organ transplants, autoimmune diseases, neurological disorders and gene therapy. For this reason, anyone suffering from AIHA has reason to hope that this drug may eventually be developed and marketed as a treatment or even a cure for this destructive blood disorder. However, additional research is still necessary to thoroughly understand all the beneficial effects of the drug.
You can visit the website www.clodrosome.com for more helpful information about Liposomal Clodronate May Offer Benefits To Those Suffering From Certain Types Of Anemia